News | May 17, 2023
Farxiga’s expanded approval highlights potential to differentiate in HF space, says GlobalData
Farxiga is expected to have such a strong influence on the market due to the impressive results
Farxiga is expected to have such a strong influence on the market due to the impressive results
ZN-A-1041 was designed to be blood-brain-barrier-penetrant, and has the potential to treat or prevent the onset of brain metastases in patients with HER2-positive metastatic breast cancer
The collaboration between CORONA and Ferring will cater to patients across India
Sun Pharma said had a teleconference call with the US Food and Drug Administration (USFDA) regarding a pulmonary embolism (serious adverse events) occurring at the 12 mg dose
It will help in bringing a significant benefit in compliance of ARV medication in the paediatric HIV treatment
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
With a focus on optimizing patient experience with next-generation oral dosage forms, the US facility complements the cutting-edge research activities of Roquette’s existing pharma innovation centers in France and Singapore
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Subscribe To Our Newsletter & Stay Updated
